LearnGlossaryMarketStocksSuperinvestorsSign in

CGEN

Compugen Ltd.

Healthcare · $222M market cap

Verdict

We can't put a fair value on CGEN right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth1.1% a year✗
Sales growth15.4% a year✓
Free cash flow growth-36.7% a year✗
Return on invested capital-2.0%✗

Follow CGEN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds CGEN. Who we track

David Katz

Matrix Asset Advisors · as of Q2 2026

$201K

93,833 shares

About Compugen Ltd.

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works